Stuart H Isaacson1, Babak Boroojerdi2, Olga Waln3, Martha McGraw4, David L Kreitzman5, Kevin Klos6, Fredy J Revilla7, Dustin Heldman8, Maureen Phillips9, Dolors Terricabras10, Michael Markowitz11, Franz Woltering12, Stan Carson13, Daniel Truong14. 1. Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton, FL, USA. Electronic address: isaacson@ParkinsonsCenter.org. 2. UCB Pharma, Monheim am Rhein, Germany. Electronic address: babak.boroojerdi@ucb.com. 3. Houston Methodist Neurological Institute, Houston, TX, USA. Electronic address: owaln@houstonmethodist.org. 4. Central Dupage Hospital/Northwestern Medicine, Winfield, IL, USA. Electronic address: martha.mcgraw@nm.org. 5. Parkinson's Disease and Movement Disorders Center of Long Island, Commack, NY, USA. Electronic address: ParkinsonsCenterLI@gmail.com. 6. Movement Disorder Clinic of Oklahoma, Tulsa, OK, USA. Electronic address: kevin.klos@mdcok.com. 7. Greenville Health System, Greenville, SC, USA; Division of Neurology, University of South Carolina School of Medicine Greenville, Greenville, SC, USA. Electronic address: frevilla@ghs.org. 8. Great Lakes NeuroTechnologies, Cleveland, OH, USA. Electronic address: dheldman@glneurotech.com. 9. Great Lakes NeuroTechnologies, Cleveland, OH, USA. Electronic address: maureen.phillips@intel.com. 10. UCB Pharma, Slough, UK. Electronic address: terricabras.dolors@gmail.com. 11. UCB Pharma, Raleigh, NC, USA. Electronic address: michael.markowitz@ucb.com. 12. UCB Pharma, Monheim am Rhein, Germany. Electronic address: franz.woltering@ucb.com. 13. UCB Pharma, Raleigh, NC, USA. Electronic address: stan.carson@ucb.com. 14. Parkinson's and Movement Disorder Institute, Fountain Valley, CA, USA. Electronic address: dtruong@pmdi.org.
Abstract
BACKGROUND: Feedback from wearable biosensors may help assess motor function in Parkinson's disease (PD) patients and titrate medication. Kinesia 360 continuously monitors motor symptoms via wrist and ankle sensors. METHODS: PD0049 was a 12-week pilot study to investigate whether using Kinesia 360 at home could improve motor symptom management in PD patients startingtransdermal dopamine agonist rotigotine. Adults with PD and insufficiently controlled motor symptoms (prescribedrotigotine) were randomized 1:1 to Control Group (CG) or Experimental Group (EG) before starting rotigotine. Motor symptoms were assessed in all patients at baseline and Week 12 (W12) using Unified PD Rating Scale (UPDRS) III and Kinesia ONE, which measures standardized motor tasks via a sensor on the index finger. Between baseline and W12, EG used Kinesia 360 at home; clinicians used the data to supplement standard care in adjusting rotigotine dosage. RESULTS: At W12, least squares mean improvements in UPDRS II (-2.1 vs 0.5, p = 0.004) and UPDRS III (-5.3 vs -1.0, p = 0.134) were clinically meaningfully greater, and mean rotigotine dosage higher (4.8 vs 3.9 mg/24 h) in EG (n = 19) vs CG (n = 20). Mean rotigotine dosage increase (+2.8 vs + 1.9 mg/24 h) and mean number of dosage changes (2.8 vs 1.8) during the study were higher in EG vs CG. Tolerability and retention rates were similar. CONCLUSION: Continuous, objective, motor symptom monitoring using a wearable biosensor as an adjunct to standard care may enhance clinical decision-making, and may improve outcomes in PD patients starting rotigotine.
RCT Entities:
BACKGROUND: Feedback from wearable biosensors may help assess motor function in Parkinson's disease (PD) patients and titrate medication. Kinesia 360 continuously monitors motor symptoms via wrist and ankle sensors. METHODS: PD0049 was a 12-week pilot study to investigate whether using Kinesia 360 at home could improve motor symptom management in PDpatients starting transdermal dopamine agonist rotigotine. Adults with PD and insufficiently controlled motor symptoms (prescribed rotigotine) were randomized 1:1 to Control Group (CG) or Experimental Group (EG) before starting rotigotine. Motor symptoms were assessed in all patients at baseline and Week 12 (W12) using Unified PD Rating Scale (UPDRS) III and Kinesia ONE, which measures standardized motor tasks via a sensor on the index finger. Between baseline and W12, EG used Kinesia 360 at home; clinicians used the data to supplement standard care in adjusting rotigotine dosage. RESULTS: At W12, least squares mean improvements in UPDRS II (-2.1 vs 0.5, p = 0.004) and UPDRS III (-5.3 vs -1.0, p = 0.134) were clinically meaningfully greater, and mean rotigotine dosage higher (4.8 vs 3.9 mg/24 h) in EG (n = 19) vs CG (n = 20). Mean rotigotine dosage increase (+2.8 vs + 1.9 mg/24 h) and mean number of dosage changes (2.8 vs 1.8) during the study were higher in EG vs CG. Tolerability and retention rates were similar. CONCLUSION: Continuous, objective, motor symptom monitoring using a wearable biosensor as an adjunct to standard care may enhance clinical decision-making, and may improve outcomes in PDpatients starting rotigotine.
Authors: Florian Lipsmeier; Cedric Simillion; Atieh Bamdadian; Rosanna Tortelli; Lauren M Byrne; Yan-Ping Zhang; Detlef Wolf; Anne V Smith; Christian Czech; Christian Gossens; Patrick Weydt; Scott A Schobel; Filipe B Rodrigues; Edward J Wild; Michael Lindemann Journal: J Med Internet Res Date: 2022-06-28 Impact factor: 7.076
Authors: Joan A O'Keefe; Deborah Bang; Erin E Robertson; Alexandras Biskis; Bichun Ouyang; Yuanqing Liu; Gian Pal; Elizabeth Berry-Kravis; Deborah A Hall Journal: Mov Disord Clin Pract Date: 2020-08-29
Authors: Jamie L Adams; Karlo J Lizarraga; Emma M Waddell; Taylor L Myers; Stella Jensen-Roberts; Joseph S Modica; Ruth B Schneider Journal: Curr Neurol Neurosci Rep Date: 2021-03-03 Impact factor: 6.030